Kailera Therapeutics, Inc.

NASDAQ:KLRA

Biotechnology

Healthcare
$11.79 +2.66%

+$0.51 today

Market cap
$1.53B
Beta
0.00
52W Low $18.50High $28.23

Volume 0.42M

Average 0.80M

KLRA Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Kailera Therapeutics, Inc.NASDAQ: KLRA

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents of $130.3M in Q2 FY2026

Q2 FY2026 cash & equivalents was $130.3M.

Context

  • Cash & equivalents amounted to 10.8% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$130.3M+16.5% QoQ
Last fiscal yearDec 2025
$160.27M— YoY
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
160.27M USD
Year-over-year change
—

Cash & Equivalents vs competitors

How KLRA compares with its peers on the latest reported figures

  • KLRA's Jun 2026 cash & equivalents of $130.3M is the 4th highest of the 10 companies compared; the peer median is $98.09M.
  • Cash & equivalents amounts to 10.8% of total assets for KLRA, versus a peer median of 60.2%.
KLRA Competitors Peer median
Cash & Equivalents for KLRA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NAMSNewAmsterdam Pharma Company N.V.Jun 2026$424.15M -24.8%+1.6%60.2%
BIOABioAge Labs, Inc.Mar 2026$241.78M -6.1%+89.8%60.8%
MBXMBX Biosciences, Inc. Common StockSep 2026$161.69M -27.5%+46.0%32.3%
KLRAKailera Therapeutics, Inc.Jun 2026$130.3M ——10.8%
VKTXViking Therapeutics, Inc.Jun 2026$125.75M +271.2%+65.4%24.1%
VTVTvTv Therapeutics Inc.Mar 2026$98.09M +215.8%+94.3%99.3%
ALTAltimmune, Inc.Mar 2026$97.6M +98.8%-26.7%29.1%
GUTSFractyl Health, Inc. Common StockMar 2026$63.17M +50.0%+18.3%63.6%
BMEABiomea Fusion, Inc.Mar 2026$44.69M +24.6%-20.7%96.4%
ORMPOramed Pharmaceuticals Inc.Mar 2026$13.2M -82.3%+4.3%4.9%
Peer median (excluding KLRA) $98.09M+24.6%+18.3%60.2%

Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kailera Therapeutics, Inc.

NASDAQ:KLRA

Intrinsic Alpha fair value

Locked

Current Price

$11.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.